Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Gynecology

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 225 articles:
HTML format



Single Articles


    April 2021
  1. CHECK JH, Check D, Poretta T, Wilson C, et al
    Palliative Benefits of Oral Mifepristone for the Treatment of Metastatic Fibroblastic Osteosarcoma.
    Anticancer Res. 2021;41:2111-2115.
    PubMed     Abstract available


  2. NASSER S, Fotopoulou C, Richter R, Kaulich J, et al
    Prognostic Value and Therapeutic Implications of Pleural Carcinosis and Malignant Pleural Effusion in Advanced Epithelial Ovarian Cancer.
    Anticancer Res. 2021;41:2033-2038.
    PubMed     Abstract available


  3. GADDUCCI A, Simonetti E, Guidoccio F, Manca G, et al
    Have Volume-based Parameters of Positron Emission Tomography/Computed Tomography Prognostic Relevance for Patients With Potentially Platinum-responsive Recurrent Ovarian Cancer? A Single Center Italian Study.
    Anticancer Res. 2021;41:1937-1944.
    PubMed     Abstract available


    March 2021
  4. YANO M, Miyazawa M, Ogane N, Ogasawara A, et al
    Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma.
    Anticancer Res. 2021;41:1647-1654.
    PubMed     Abstract available


  5. KWON HJ, Song SY, Kim HS
    Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma.
    Anticancer Res. 2021;41:1579-1586.
    PubMed     Abstract available


  6. MEYER HJ, Wienke A, Surov A
    Pre-treatment Apparent Diffusion Coefficient Does Not Predict Therapy Response to Radiochemotherapy in Cervical Cancer: A Systematic Review and Meta-analysis.
    Anticancer Res. 2021;41:1163-1170.
    PubMed     Abstract available


    February 2021
  7. MIYAMOTO M, Hada T, Ishibashi H, Iwahashi H, et al
    A New Model to Improve the Prediction of Prognosis of Endometrial Carcinoma by Combining Traditional Classification With the Presence of Tumor-infiltrating Lymphocytes.
    Anticancer Res. 2021;41:1047-1053.
    PubMed     Abstract available


  8. JOCHUM F, Aubry G, Pellerin M, Billard C, et al
    Relevance of Laparoscopic Surgery for Ovarian Cancer in Well-selected Patients: A Propensity-matched Comparison With Laparotomy.
    Anticancer Res. 2021;41:955-965.
    PubMed     Abstract available


  9. MANDATO VD, Torricelli F, Mastrofilippo V, Pirillo D, et al
    Impact of a Province-wide Endometrial Cancer Guideline on Daily Practice.
    Anticancer Res. 2021;41:937-948.
    PubMed     Abstract available


  10. URPILAINEN E, Arima R, Karihtala P, Puistola U, et al
    Metformin Associates With Aggressive Features of Endometrial Cancer in Women With Type 2 Diabetes.
    Anticancer Res. 2021;41:821-828.
    PubMed     Abstract available


  11. KIM HJ, Heo K
    YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation.
    Anticancer Res. 2021;41:671-678.
    PubMed     Abstract available


  12. EGGER EK, Stope MB, Recker F, Konsgen D, et al
    Lower Genital Tract Melanomas: Staging, Predictors of Outcome, and New Therapeutic Options.
    Anticancer Res. 2021;41:999-1004.
    PubMed     Abstract available


    January 2021
  13. DI MARTINO G, Lissoni AA, Ferrari D, DI Meo ML, et al
    Dose-dense Neoadjuvant Chemotherapy With Paclitaxel and Carboplatin in Cervical Cancer: Efficacy on Pathological Response.
    Anticancer Res. 2021;41:497-502.
    PubMed     Abstract available


  14. SHIMIZU Y, Suzuki S, Ukai M, Hattori S, et al
    The Prognostic Significance of Peritumoral Lymphocytes' Band-like Structure in Type II Endometrial Cancer.
    Anticancer Res. 2021;41:249-258.
    PubMed     Abstract available


  15. GADDUCCI A, Cosio S
    The Prognostic Relevance of Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Gynecological Cancer.
    Anticancer Res. 2021;41:9-20.
    PubMed     Abstract available


    December 2020
  16. CHECK JH, Check D, Srivastava MD, Poretta T, et al
    Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life.
    Anticancer Res. 2020;40:6997-7001.
    PubMed     Abstract available


  17. SOPO M, Anttila M, Muukkonen OT, YlA-Herttuala S, et al
    Microvessels in Epithelial Ovarian Tumors: High Microvessel Density Is a Significant Feature of Malignant Ovarian Tumors.
    Anticancer Res. 2020;40:6923-6931.
    PubMed     Abstract available


  18. LU KW, Yang MD, Peng SF, Chen JC, et al
    Maslinic Acid Induces DNA Damage and Impairs DNA Repair in Human Cervical Cancer HeLa Cells.
    Anticancer Res. 2020;40:6869-6877.
    PubMed     Abstract available


  19. MIYAZAWA M, Yasuda M, Miyazawa M, Ogane N, et al
    Hypoxia-inducible Factor-1alpha Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration.
    Anticancer Res. 2020;40:6791-6798.
    PubMed     Abstract available


  20. DE BREE E, Katsougkri D, Polioudaki H, Tsangaridou E, et al
    Hyperthermia During Intraperitoneal Chemotherapy With Paclitaxel or Docetaxel for Ovarian Cancer: Is There Any Benefit?
    Anticancer Res. 2020;40:6769-6780.
    PubMed     Abstract available


  21. FILIPPOV-LEVY N, Davidson B, Reich R
    The Biological Role of the Long Non-coding RNA LINK-A in Ovarian Carcinoma.
    Anticancer Res. 2020;40:6677-6684.
    PubMed     Abstract available


  22. GULIYEVA G, Huayllani MT, Avila FR, Boczar D, et al
    Younger Age as a Risk Factor for Gynecologic Cancer-related Lymphedema: A Systematic Review.
    Anticancer Res. 2020;40:6609-6612.
    PubMed     Abstract available


    November 2020
  23. LEE S, Jun J, Kim WJ, Tamayo P, et al
    WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.
    Anticancer Res. 2020;40:6017-6028.
    PubMed     Abstract available


  24. HUFFMAN D, Wegner R, Jalil A, Krivak T, et al
    Survival After Primary Surgery Compared With Neoadjuvant Chemotherapy in Early-stage Ovarian Cancer.
    Anticancer Res. 2020;40:6003-6008.
    PubMed     Abstract available


  25. GADDUCCI A, Cosio S, Fruzzetti F
    Estro-progestin Contraceptives and Risk of Cervical Cancer: A Debated Issue.
    Anticancer Res. 2020;40:5995-6002.
    PubMed     Abstract available


    October 2020
  26. MITSOPOULOS V, Innamaa A, Lippiatt J, Plevris N, et al
    Radical Surgical Procedures in Advanced Ovarian Cancer and Differences Between Primary and Interval Debulking Surgery.
    Anticancer Res. 2020;40:5869-5875.
    PubMed     Abstract available


  27. CHINCZEWSKI L, Taube ET, Feldhaus FW, DrOge LA, et al
    Angiosarcomas of Primary Gynecologic Origin - A Case Series and Review of the Literature.
    Anticancer Res. 2020;40:5743-5750.
    PubMed     Abstract available


  28. MINAGAWA Y, Ishino K, Wada R, Kudo M, et al
    High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear-cell Carcinoma.
    Anticancer Res. 2020;40:5631-5639.
    PubMed     Abstract available


  29. OH CK, Park JJ, Ha M, Heo HJ, et al
    LRRC17 Is Linked to Prognosis of Ovarian Cancer Through a p53-dependent Anti-apoptotic Function.
    Anticancer Res. 2020;40:5601-5609.
    PubMed     Abstract available


  30. HSIEH Y, Tseng JJ
    Azidothymidine (AZT) Inhibits Proliferation of Human Ovarian Cancer Cells by Regulating Cell Cycle Progression.
    Anticancer Res. 2020;40:5517-5527.
    PubMed     Abstract available


  31. YOSHINO AI, Kobayashi E, Kodama M, Hashimoto K, et al
    Oncological and Reproductive Outcomes of Abdominal Radical Trachelectomy.
    Anticancer Res. 2020;40:5939-5947.
    PubMed     Abstract available


  32. SHIBA S, Wakatsuki M, Ohno T, Nakano T, et al
    Differences in Linear Energy Transfer Affect Cell-killing and Radiosensitizing Effects of Spread-out Carbon-ion Beams.
    Anticancer Res. 2020;40:5497-5502.
    PubMed     Abstract available


    September 2020
  33. TANIGAWA T, Matoda M, Omi M, Aoki Y, et al
    Continuous Administration of Bevacizumab After Disease Progression in Recurrent Ovarian Cancer: A Retrospective Observational Study.
    Anticancer Res. 2020;40:5285-5290.
    PubMed     Abstract available


  34. SOEDA S, Watanabe T, Kamo N, Sato T, et al
    Successful Management of Platinum-resistant Ovarian Cancer by Weekly Nedaplatin Followed by Olaparib: Three Case Reports.
    Anticancer Res. 2020;40:5263-5270.
    PubMed     Abstract available


  35. MADSEN CV, Adimi P, Jakobsen A, Steffensen KD, et al
    Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer.
    Anticancer Res. 2020;40:5255-5261.
    PubMed     Abstract available


  36. GADDUCCI A, Cosio S
    Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: Review of the Literature and Perspectives of Clinical Research.
    Anticancer Res. 2020;40:4819-4828.
    PubMed     Abstract available


    August 2020
  37. AKAZAWA M, Hashimoto K
    Artificial Intelligence in Ovarian Cancer Diagnosis.
    Anticancer Res. 2020;40:4795-4800.
    PubMed     Abstract available


  38. GOTO S, Terao Y, Kamigaki T, Takimoto R, et al
    Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix.
    Anticancer Res. 2020;40:4741-4748.
    PubMed     Abstract available


  39. TAKIMOTO R, Kamigaki T, Okada S, Ibe H, et al
    Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study.
    Anticancer Res. 2020;40:4729-4740.
    PubMed     Abstract available


  40. FIORI E, Crocetti D, Lamazza A, DE Felice F, et al
    Is Low Inferior Mesenteric Artery Ligation Worthwhile to Prevent Urinary and Sexual Dysfunction After Total Mesorectal Excision for Rectal Cancer?
    Anticancer Res. 2020;40:4223-4228.
    PubMed     Abstract available


    July 2020
  41. YANO M, Aso S, Sato M, Aoyagi Y, et al
    Pembrolizumab and Radiotherapy for Platinum-refractory Recurrent Uterine Carcinosarcoma With an Abscopal Effect: A Case Report.
    Anticancer Res. 2020;40:4131-4135.
    PubMed     Abstract available


  42. CRESTANI A, Theodore C, Levaillant JM, Thomassin-Naggara I, et al
    Magnetic Resonance and Ultrasound Fusion Imaging to Characterise Ovarian Masses: A Feasibility Study.
    Anticancer Res. 2020;40:4115-4121.
    PubMed     Abstract available


  43. SELLE F, Heudel PE, Hardy-Bessard AC, Pozet A, et al
    GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
    Anticancer Res. 2020;40:3939-3945.
    PubMed     Abstract available


  44. GLOVER O, Asher V, Bali A, Abdul S, et al
    Primary and Interval Debulking Surgery Provide Similar Survival and Platinum Sensitivity Outcomes in Advanced Ovarian Cancer: A Retrospective Study.
    Anticancer Res. 2020;40:3925-3929.
    PubMed     Abstract available


  45. PAN Y, Chiu YH, Chiu SC, Cho DY, et al
    Cytokine-induced Killer T Cells Enhance the Cytotoxicity Against Carboplatin-resistant Ovarian Cancer Cells.
    Anticancer Res. 2020;40:3865-3872.
    PubMed     Abstract available


  46. HARAGA J, Nakamura K, Haruma T, Nyuya A, et al
    Molecular Characterization of Second Primary Endometrial Cancer.
    Anticancer Res. 2020;40:3811-3818.
    PubMed     Abstract available


  47. THEOFANAKIS C, Haidopoulos D, Thomakos N, Rodolakis A, et al
    Minimizing Fertility-sparing Treatment for Low Volume Early Stage Cervical Cancer; Is Less the (R)Evolution?
    Anticancer Res. 2020;40:3651-3658.
    PubMed     Abstract available


    June 2020
  48. SHIMOJI Y, Nagai Y, Toita T, Ariga T, et al
    A Phase II Study of Neoadjuvant Chemotherapy Followed by Extended Field Concurrent Chemoradiotherapy for Para-aortic Lymph Node Positive Cervical Cancer.
    Anticancer Res. 2020;40:3565-3570.
    PubMed     Abstract available


  49. VLASAK P, Bouda J, Kostun J, Berezovskiy D, et al
    Diagnostic Reliability, Accuracy and Safety of Ultrasound-guided Biopsy and Ascites Puncture in Primarily Inoperable Ovarian Tumours.
    Anticancer Res. 2020;40:3527-3534.
    PubMed     Abstract available


  50. SINGH P, Mantilla E, Sewell J, Hatanpaa KJ, et al
    Occurrence of Glioma in Pregnant Patients: An Institutional Case Series and Review of the Literature.
    Anticancer Res. 2020;40:3453-3457.
    PubMed     Abstract available


  51. KUITTINEN T, Rovio P, Luukkaala T, Laurila M, et al
    Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells In Vitro.
    Anticancer Res. 2020;40:3129-3138.
    PubMed     Abstract available


  52. KOUTRAS A, Peteinaris A, Davakis S, Kalinterakis G, et al
    Surgical Versus Conservative Treatment for Endometrial Cancer in Women of Reproductive Age: Incidence of Urinary Tract Symptoms.
    Anticancer Res. 2020;40:3065-3069.
    PubMed     Abstract available


  53. DIETL A, Aumann K, Beckmann MW
    Tumor Handling of Early-stage Cervical Cancer: A Literature Analysis of Villoglandular Adenocarcinoma of the Cervix.
    Anticancer Res. 2020;40:3049-3053.
    PubMed     Abstract available


  54. GADDUCCI A, Pistolesi S, Cosio S, Naccarato AG, et al
    Is Perineural Invasion a Novel Prognostic Factor Useful to Tailor Adjuvant Treatment in Patients Treated With Primary Surgery for Cervical and Vulvar Carcinoma?
    Anticancer Res. 2020;40:3031-3037.
    PubMed     Abstract available


    May 2020
  55. LIAKOU CG, LA Russa MC, Akrivos N, Ames V, et al
    The Role of Magnetic Resonance Imaging in the Pre-operative Evaluation of Women Diagnosed With Atypical Endometrial Hyperplasia.
    Anticancer Res. 2020;40:2989-2993.
    PubMed     Abstract available


  56. HAN Q, Tan Y, Hoffman RM
    Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.
    Anticancer Res. 2020;40:2813-2819.
    PubMed     Abstract available


  57. EKMANN-GADE AW, Hogdall CK, Engelholm SA, Fago-Olsen CL, et al
    Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer.
    Anticancer Res. 2020;40:2765-2770.
    PubMed     Abstract available


  58. MAEDA O, Kajiyama H, Shibata K, Nakamura S, et al
    Pegylated Liposomal Doxorubicin/Oxaliplatin Chemotherapy Can Overcome Cisplatin Resistance in Spectrin alphaII-Overexpressing Ovarian Carcinoma.
    Anticancer Res. 2020;40:2497-2507.
    PubMed     Abstract available


  59. GADDUCCI A, Zannoni GF
    Endometriosis-associated Extraovarian Malignancies: A Challenging Question for the Clinician and the Pathologist.
    Anticancer Res. 2020;40:2429-2438.
    PubMed     Abstract available


    April 2020
  60. LIAKOU CG, Akrivos N, Kumar B, Duncan TJ, et al
    Cholecystectomy as Part of Cytoreductive Surgery for Advanced Ovarian Cancer: Perioperative Outcomes.
    Anticancer Res. 2020;40:2331-2336.
    PubMed     Abstract available


  61. RADES D, Nguyen T, Janssen S, Schild SE, et al
    An Instrument to Guide Physicians when Estimating the Survival of Elderly Patients With Brain Metastasis from Gynecological Cancer.
    Anticancer Res. 2020;40:2257-2260.
    PubMed     Abstract available


  62. GADDUCCI A, Simonetti E, Manca G, Guidoccio F, et al
    Positron Emission Tomography/Computed Tomography in Platinum-sensitive Recurrent Ovarian Cancer: A Single-center Italian Study.
    Anticancer Res. 2020;40:2191-2197.
    PubMed     Abstract available


  63. JELSKI W, Piechota J, Orywal K, Mroczko B, et al
    The Alterations in Alcohol Dehydrogenase Activity in the Sera of Women With Intrahepatic Cholestasis of Pregnancy.
    Anticancer Res. 2020;40:1997-2001.
    PubMed     Abstract available


  64. MORTAKI D, Tsitsopoulos E, Louizou E, Tsiambas E, et al
    Prevalence of Cervico-vaginal High-risk HPV Types and Other Sexually Transmitted Pathogens in Anogenital Warts Patients.
    Anticancer Res. 2020;40:2219-2223.
    PubMed     Abstract available


    March 2020
  65. VAGIOS S, Doulgeraki T, Giannikaki E, Kavoura E, et al
    Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?
    Anticancer Res. 2020;40:1669-1676.
    PubMed     Abstract available


  66. PAULY L, Benoit L, Koskas M
    Impact of Extent of Lymphadenectomy on Survival in Patients With Endometrial Cancer: A Matched Cohort Study.
    Anticancer Res. 2020;40:1563-1570.
    PubMed     Abstract available


  67. GADDUCCI A, Cosio S, Lissoni AA, Zizioli V, et al
    Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study.
    Anticancer Res. 2020;40:1543-1550.
    PubMed     Abstract available


  68. FRIEDRICH M, Zinn W, Kolnsberg L, Kraft C, et al
    Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer: Evaluation of Side Effects in a Single Institution Cohort.
    Anticancer Res. 2020;40:1481-1486.
    PubMed     Abstract available


  69. HUNG PS, Chuang FJ, Chen CY, Chou CH, et al
    miR-187* Enhances SiHa Cervical Cancer Cell Oncogenicity Via Suppression of WWOX.
    Anticancer Res. 2020;40:1427-1436.
    PubMed     Abstract available


  70. HAYASHI T, Sano K, Ichimura T, Kanai Y, et al
    Characteristics of Leiomyosarcoma: Induction of Hematogenous Metastasis by Isolated Uterine Mesenchymal Tumor Stem-like Cells.
    Anticancer Res. 2020;40:1255-1265.
    PubMed     Abstract available


  71. RIZZO A, Ricci AD, Saponara M, DE Leo A, et al
    Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art.
    Anticancer Res. 2020;40:1229-1238.
    PubMed     Abstract available


  72. MEKURIA S, Jerkeman M, Forslund O, Fikru S, et al
    Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women.
    Anticancer Res. 2020;40:1513-1517.
    PubMed     Abstract available


    February 2020
  73. MUROFUSHI KN, Yoshioka Y, Ishikawa H, Sumi M, et al
    Selection Criteria and Clinical Outcomes of Patients With Asymmetrical Cervical Cancer Treated With Various High-dose-rate Brachytherapy Techniques.
    Anticancer Res. 2020;40:999-1006.
    PubMed     Abstract available


  74. PHILIPOVSKIY A, Campbell A, Heydarian R, Castillo B, et al
    Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer.
    Anticancer Res. 2020;40:857-864.
    PubMed     Abstract available


  75. ADOMAITIENE L, Nadisauskiene R, Nickkho-Amiry M, Cizauskas A, et al
    Tumor Suppression in Asymptomatic Postmenopausal Endometrial Polyps.
    Anticancer Res. 2020;40:789-794.
    PubMed     Abstract available


  76. IWASAKI T, Kohashi K, Ohno M, Taguchi T, et al
    Establishment and Characterization of a Novel Primitive Yolk Sac Tumour Cell Line, TC587.
    Anticancer Res. 2020;40:759-766.
    PubMed     Abstract available


    January 2020
  77. KOLNSBERG L, Riffelmann M, Friedrich M
    Comparison of Serum 25-Hydroxyvitamin D Levels in Patients With Malignant and Benign Gynaecological Disease.
    Anticancer Res. 2020;40:545-550.
    PubMed     Abstract available


  78. LEE HJ, Kim JM, Chin YJ, Chong GO, et al
    Prognostic Value of Hematological Parameters in Locally Advanced Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy.
    Anticancer Res. 2020;40:451-458.
    PubMed     Abstract available


  79. LI J, Vangundy Z, Poi M
    PTC209, a Specific Inhibitor of BMI1, Promotes Cell Cycle Arrest and Apoptosis in Cervical Cancer Cell Lines.
    Anticancer Res. 2020;40:133-141.
    PubMed     Abstract available


    December 2019
  80. ROH HJ, Go EB, Kim KB, Lee JH, et al
    The Diagnostic Accuracy and Postoperative Outcomes of Cervical Cancer Patients for MR-invisible or MR-visible Diagnosis of Combined T2- and Diffusion-weighted 3T MRI Using the External Phased-array Receiver.
    Anticancer Res. 2019;39:6945-6956.
    PubMed     Abstract available


  81. MERENTITIS D, Nguyen BD, Samartzis EP, Noske A, et al
    Loss of MDC1 in Endometrial Carcinoma Is Associated With Loss of MRN Complex and MMR Deficiency.
    Anticancer Res. 2019;39:6547-6553.
    PubMed     Abstract available


    November 2019
  82. SIDORKIEWICZ I, Piskor B, Dabrowska E, Guzinska-Ustymowicz K, et al
    Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.
    Anticancer Res. 2019;39:6403-6412.
    PubMed     Abstract available


  83. COOSEMANS AN, Baert T, D'Heygere V, Wouters R, et al
    Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer.
    Anticancer Res. 2019;39:5953-5962.
    PubMed     Abstract available


    October 2019
  84. WAFA M, Braicu EI, Muallem MZ, Richter R, et al
    Incidence and Pattern of Spread of Lymph Node Metastasis in Patients With Low-grade Serous Ovarian Cancer.
    Anticancer Res. 2019;39:5617-5621.
    PubMed     Abstract available


  85. KAWASHIMA N, Yoshida H, Miwa M, Fujiwara K, et al
    MLH1 Is a Prognostic Biomarker for Serous Ovarian Cancer Treated With Platinum- and Taxane-based Chemotherapy.
    Anticancer Res. 2019;39:5505-5513.
    PubMed     Abstract available


    September 2019
  86. KOSCIELNY A, Ko A, Egger EK, Kuhn W, et al
    Prevention of Anastomotic Leakage in Ovarian Cancer Debulking Surgery and Its Impact on Overall Survival.
    Anticancer Res. 2019;39:5209-5218.
    PubMed     Abstract available


  87. NASIOUDIS D, Wilson E, Mastroyannis SA, Sisti G, et al
    Increased Risk of Breast and Uterine Cancer Among Women With Ovarian Granulosa Cell Tumors.
    Anticancer Res. 2019;39:4971-4975.
    PubMed     Abstract available


  88. SLETTEN ET, Arnes M, Vereide AB, Orbo A, et al
    Intrauterine Progestin Therapy as a New Approach to Premalignant Endometrial Polyps: A Prospective Observational Study.
    Anticancer Res. 2019;39:4897-4903.
    PubMed     Abstract available


  89. TAMARI K, Sano K, Li Z, Seo Y, et al
    Ro 90-7501 Is a Novel Radiosensitizer for Cervical Cancer Cells that Inhibits ATM Phosphorylation.
    Anticancer Res. 2019;39:4805-4810.
    PubMed     Abstract available


  90. KIM Y, Kim YS, Kim M, Kim JM, et al
    Thioredoxin-interacting Protein (TXNIP) Mediates Thioredoxin-dependent Antioxidant Mechanism in Endometrial Cancer Cells Treated With 1alpha,25-dihydroxyvitamin D3.
    Anticancer Res. 2019;39:4795-4803.
    PubMed     Abstract available


  91. YASUDA M, Kishimoto S, Amano M, Fukushima S, et al
    Comparison of Pregnane X Receptor Antagonists for Enhancing the Antitumor Effect of Cisplatin.
    Anticancer Res. 2019;39:4749-4755.
    PubMed     Abstract available


  92. KOMORI K, Kinoshita T, Oshiro T, Ouchi A, et al
    Surgical Strategy for Rectovaginal Fistula After Colorectal Anastomosis at a High-volume Cancer Center According to Image Type and Colonoscopy Findings.
    Anticancer Res. 2019;39:5097-5103.
    PubMed     Abstract available


  93. BORGHESE M, Razzore P, Ferrero A, Daniele L, et al
    Metastatic Bilateral Strumal Carcinoid: A Case Report and Review of the Literature.
    Anticancer Res. 2019;39:5053-5056.
    PubMed     Abstract available


    August 2019
  94. MIYAHARA D, Yotsumoto F, Hirakawa T, Yoshikawa K, et al
    Clinical Features of Recurrence in Patients Without Residual Tumour in Endometrial Cancer.
    Anticancer Res. 2019;39:4581-4588.
    PubMed     Abstract available


  95. KOMATSU H, Oishi T, Sato S, Osaku D, et al
    Evaluating Chemotherapy-induced Nausea and Vomiting and Food Intake in Patients With Gynecologic Cancer.
    Anticancer Res. 2019;39:4555-4560.
    PubMed     Abstract available


  96. AN HJ, Song DH
    Displacement of Vitamin D Receptor Is Related to Lower Histological Grade of Endometrioid Carcinoma.
    Anticancer Res. 2019;39:4143-4147.
    PubMed     Abstract available


  97. LOHSE I, Azzam DJ, Al-Ali H, Volmar CH, et al
    Ovarian Cancer Treatment Stratification Using Ex Vivo Drug Sensitivity Testing.
    Anticancer Res. 2019;39:4023-4030.
    PubMed     Abstract available


  98. GLORIE N, Baert T, VAN DEN Bosch T, Coosemans AN, et al
    Circulating Protein Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas.
    Anticancer Res. 2019;39:3981-3989.
    PubMed     Abstract available


    July 2019
  99. ALAMPI DM, Ciusani E, Carenini N, Corna E, et al
    AXL Downstream Targeting Unravels Synergistic Drug Combinations in Ovarian Carcinoma Cells.
    Anticancer Res. 2019;39:3803-3808.
    PubMed     Abstract available


  100. LIN CH, Peng SF, Chueh FS, Cheng ZY, et al
    The Ethanol Crude Extraction of Cyperus Rotundus Regulates Apoptosis-associated Gene Expression in HeLa Human Cervical Carcinoma Cells In Vitro.
    Anticancer Res. 2019;39:3697-3709.
    PubMed     Abstract available


  101. YASUDA M, Kishimoto S, Amano M, Fukushima S, et al
    The Involvement of Pregnane X Receptor-regulated Pathways in the Antitumor Activity of Cisplatin.
    Anticancer Res. 2019;39:3601-3608.
    PubMed     Abstract available


  102. PAN C, Onda K, Hirano T
    Bevacizumab Versus Anti-preeclamptic Drugs: Evaluation With Three-dimensionally Co-cultured Human Mini Tumors.
    Anticancer Res. 2019;39:3543-3551.
    PubMed     Abstract available


    June 2019
  103. CECHOVA M, Chocholaty M, Zima T, Babjuk M, et al
    The Significance of Pregnancy-associated Plasma Protein a Serum Concentration in Clear Cell Renal Cell Carcinoma.
    Anticancer Res. 2019;39:3249-3253.
    PubMed     Abstract available


  104. LIN YC, Chen RY, Liang JA, Hung YC, et al
    Immunohistochemical Biomarkers of Survival in Patients With Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy.
    Anticancer Res. 2019;39:3231-3240.
    PubMed     Abstract available


  105. GOSSET M, Chargari C, Bentivegna E, Leary A, et al
    Should We Cease to Perform Salvage Hysterectomy After Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer?
    Anticancer Res. 2019;39:2919-2926.
    PubMed     Abstract available


  106. JUNG YY, Woo HY, Kim HS
    Targeted Genomic Sequencing Reveals Novel TP53 In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma.
    Anticancer Res. 2019;39:2883-2889.
    PubMed     Abstract available


  107. CHEN SW, Liang JA, Hung YC, Yeh LS, et al
    Effectiveness of Image-guided Brachytherapy in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy.
    Anticancer Res. 2019;39:3015-3024.
    PubMed     Abstract available


    May 2019
  108. RATIU D, Luncescu C, Morgenstern B, Eichler C, et al
    Comparison of Minimally Invasive Surgery and Abdominal Surgery Among Patients With Cervical Cancer.
    Anticancer Res. 2019;39:2661-2664.
    PubMed     Abstract available


  109. CUCCIA F, Mortellaro G, Cespuglio D, Valenti V, et al
    A Case Report of Adult Pineoblastoma Occurring in a Pregnant Woman.
    Anticancer Res. 2019;39:2627-2631.
    PubMed     Abstract available


  110. BEDKOWSKA GE, Piskor B, Gacuta E, Zajkowska M, et al
    Diagnostic Power of Selected Cytokines, MMPs and TIMPs in Ovarian Cancer Patients - ROC Analysis.
    Anticancer Res. 2019;39:2575-2582.
    PubMed     Abstract available


  111. GADDUCCI A, Giuliani D, Cosio S, Lissoni A, et al
    Clinical Outcome of Patients With Malignant Tumors Associated With Mature Cystic Teratomas of the Ovary: A Retrospective Multicenter Italian Study.
    Anticancer Res. 2019;39:2513-2517.
    PubMed     Abstract available


  112. CHRISTENSEN MV, Hogdall C, Jensen SG, Lokman N, et al
    Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer.
    Anticancer Res. 2019;39:2475-2482.
    PubMed     Abstract available


  113. PIRES LV, Yi Y, Cheng JC, Pizzolato LS, et al
    Lapatinib Inhibits Amphiregulin-induced BeWo Choriocarcinoma Cell Proliferation by Reducing ERK1/2 and AKT Signaling Pathways.
    Anticancer Res. 2019;39:2377-2383.
    PubMed     Abstract available


  114. KIM JY, Kim SH, Kim HS
    Promoter Methylation Down-regulates Osteoprotegerin Expression in Ovarian Carcinoma.
    Anticancer Res. 2019;39:2361-2367.
    PubMed     Abstract available


  115. KORHEGYI Z, Rozsa D, Hajdu I, Bodnar M, et al
    Synthesis of (68)Ga-Labeled Biopolymer-based Nanoparticle Imaging Agents for Positron-emission Tomography.
    Anticancer Res. 2019;39:2415-2427.
    PubMed     Abstract available


    April 2019
  116. MIYAMOTO M, Takano M, Tsuda H, Ishibashi H, et al
    Zone Formation of Lymphocyte Infiltration at the Invasive Front Results in the Prolonged Survival of Individuals With Endometrial Serous Carcinoma and Endometrioid Carcinoma With Serous Component.
    Anticancer Res. 2019;39:2085-2089.
    PubMed     Abstract available


  117. CHECK JH, Check D, Poretta T
    Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.
    Anticancer Res. 2019;39:1923-1926.
    PubMed     Abstract available


  118. KUBOTA Y, Ohno T, Kawashima M, Murata K, et al
    Development of a Vaginal Immobilization Device: A Treatment-planning Study of Carbon-ion Radiotherapy and Intensity-modulated Radiation Therapy for Uterine Cervical Cancer.
    Anticancer Res. 2019;39:1915-1921.
    PubMed     Abstract available


  119. JELENIEWICZ W, Cybulski M, Nowakowski A, Stenzel-Bembenek A, et al
    MMP-2 mRNA Expression in Ovarian Cancer Tissues Predicts Patients' Response to Platinum-Taxane Chemotherapy.
    Anticancer Res. 2019;39:1821-1827.
    PubMed     Abstract available


    March 2019
  120. REZNICZEK GA, Grunwald C, Hilal Z, Scheich J, et al
    ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).
    Anticancer Res. 2019;39:1267-1273.
    PubMed     Abstract available


    February 2019
  121. MATSUOKA H, Nakamura K, Matsubara Y, Ida N, et al
    Sarcopenia Is Not a Prognostic Factor of Outcome in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy or Radiotherapy.
    Anticancer Res. 2019;39:933-939.
    PubMed     Abstract available


  122. UNO T, Kanazawa A, Nemoto MW, Harada R, et al
    Radiation Therapy for Extrapelvic Lymph Node Recurrence After Curative Treatment for Cervical Cancer.
    Anticancer Res. 2019;39:891-895.
    PubMed     Abstract available


  123. TRYBUS W, Krol T, Trybus E, Stachurska A, et al
    Emodin Induces Death in Human Cervical Cancer Cells Through Mitotic Catastrophe.
    Anticancer Res. 2019;39:679-686.
    PubMed     Abstract available


  124. LEGROS M, Margueritte F, Tardieu A, Deluche E, et al
    Para-aortic Lymph Node Invasion in High-risk Endometrial Cancer: Performance of (18)FDG PET-CT.
    Anticancer Res. 2019;39:619-625.
    PubMed     Abstract available


  125. YAMAMOTO M, Suzuki S, Togashi K, Sanomachi T, et al
    AS602801 Sensitizes Ovarian Cancer Stem Cells to Paclitaxel by Down-regulating MDR1.
    Anticancer Res. 2019;39:609-617.
    PubMed     Abstract available


  126. AHTIKOSKI AM, Kangas J, Salonen R, Puistola U, et al
    Cytoplasmic Keap1 Expression Is Associated With Poor Prognosis in Endometrial Cancer.
    Anticancer Res. 2019;39:585-590.
    PubMed     Abstract available


  127. RASK L, Hogdall CK, Kjaer SK, Christensen L, et al
    Association of CD31 and p53 With Survival of Ovarian Cancer Patients.
    Anticancer Res. 2019;39:567-576.
    PubMed     Abstract available


  128. SIDERIS M, Emin EI, Abdullah Z, Hanrahan J, et al
    The Role of KRAS in Endometrial Cancer: A Mini-Review.
    Anticancer Res. 2019;39:533-539.
    PubMed     Abstract available


    January 2019
  129. KLAT J, Mladenka A, Dvorackova J, Bajsova S, et al
    L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB.
    Anticancer Res. 2019;39:421-424.
    PubMed     Abstract available


  130. SAKAGUCHI M, Maebayashi T, Aizawa T, Ishibashi N, et al
    Risk Factors for Sacral Insufficiency Fractures in Cervical Cancer After Whole Pelvic Radiation Therapy.
    Anticancer Res. 2019;39:361-367.
    PubMed     Abstract available


  131. KIM JH, Yoon YS, Kim JC, Kim YM, et al
    Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer.
    Anticancer Res. 2019;39:313-318.
    PubMed     Abstract available


  132. SHIMOKAWA M, Hayashi T, Kogawa T, Matsui R, et al
    Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy.
    Anticancer Res. 2019;39:225-230.
    PubMed     Abstract available


  133. ERNSTSON A, Asciutto KC, Sturesson J, Noren J, et al
    Detection of HPV mRNA in Self-collected Vaginal Samples Among Women at 69-70 Years of Age.
    Anticancer Res. 2019;39:381-386.
    PubMed     Abstract available


    December 2018
  134. EOH KJ, Park HS, Park JS, Lee ST, et al
    Distinct Clinical Courses of Epithelial Ovarian Cancer with Mutations in BRCA1 5' and 3' Exons.
    Anticancer Res. 2018;38:6947-6953.
    PubMed     Abstract available


  135. YAMAMOTO M, Suzuki S, Togashi K, Sanomachi T, et al
    AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel.
    Anticancer Res. 2018;38:6699-6706.
    PubMed     Abstract available


  136. LARBRE V, Alyami M, Mercier F, Vantard N, et al
    No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis.
    Anticancer Res. 2018;38:6869-6875.
    PubMed     Abstract available


  137. DE LIMA TM, DE Azevedo Focchi GR, DE Almeida BC, Belfort-Mattos PN, et al
    Expression of CK7 and CDKN2 in Cervical Intraepithelial Neoplasia and Correlation with Clinical Outcome.
    Anticancer Res. 2018;38:6673-6681.
    PubMed     Abstract available


    November 2018
  138. PETRU E, Huber C, Sampl E, Haas J, et al
    Comparison of Primary Tumor Size in Stage I and III Epithelial Ovarian Cancer.
    Anticancer Res. 2018;38:6507-6511.
    PubMed     Abstract available


    October 2018
  139. DILLEY J, Pratt P, Kyrgiou M, Flott K, et al
    Current and Future Use of Radiological Images in the Management of Gynecological Malignancies - A Survey of Practice in the UK.
    Anticancer Res. 2018;38:5867-5876.
    PubMed     Abstract available


  140. GRABOWSKI JP, Richter R, Rittmeister H, Chekerov R, et al
    Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients.
    Anticancer Res. 2018;38:5853-5858.
    PubMed     Abstract available


  141. TSIAMBAS E, Riziotis C, Mastronikolis NS, Peschos D, et al
    Comparative p16(IKN4A) Expression in Laryngeal Carcinoma and Cervical Cancer Precursors: A Real-time Grid-based Immunocytochemistry Analysis.
    Anticancer Res. 2018;38:5805-5810.
    PubMed     Abstract available


  142. KOUKOURAKIS MI, Kontomanolis E, Sotiropoulou M, Mitrakas A, et al
    Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200.
    Anticancer Res. 2018;38:5739-5745.
    PubMed     Abstract available


  143. AFROZE SH, Peddaboina C, McDowell AB Jr, Ashraf AHMZ, et al
    Differential Effects of In Vitro Treatment with Cinobufotalin on Three Types of Ovarian Cancer Cells.
    Anticancer Res. 2018;38:5717-5724.
    PubMed     Abstract available


    September 2018
  144. LAFLEUR J, Hefler-Frischmuth K, Grimm C, Schwameis R, et al
    Prognostic Value of Serum Creatinine Levels in Patients with Epithelial Ovarian Cancer.
    Anticancer Res. 2018;38:5127-5130.
    PubMed     Abstract available


  145. ZHU Z, Zhao L, Brittingham A, Bai Q, et al
    Trichomonas Vaginalis Inhibits HeLa Cell Growth Through Modulation of Critical Molecules for Cell Proliferation and Apoptosis.
    Anticancer Res. 2018;38:5079-5086.
    PubMed     Abstract available


  146. PARK CK, Kim HS
    Clinicopathological Characteristics of Ovarian Metastasis from Colorectal and Pancreatobiliary Carcinomas Mimicking Primary Ovarian Mucinous Tumor.
    Anticancer Res. 2018;38:5465-5473.
    PubMed     Abstract available


  147. MENDIOLA M, Redondo A, Heredia-Soto V, Herranz J, et al
    Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
    Anticancer Res. 2018;38:5393-5400.
    PubMed     Abstract available


  148. SMOLARZ B, Michalska MM, Samulak D, Wojcik L, et al
    Studies of Correlations Between Single Nucleotide Polymorphisms of DNA Repair Genes and Endometrial Cancer in Polish Women.
    Anticancer Res. 2018;38:5223-5229.
    PubMed     Abstract available


  149. ASHRAF AHMZ, Afroze SH, Yamauchi K, Zawieja DC, et al
    Differential Mechanism of Action of 3,4',7-O-trimethylquercetin in Three Types of Ovarian Cancer Cells.
    Anticancer Res. 2018;38:5131-5137.
    PubMed     Abstract available


    August 2018
  150. PARASHKEVOVA A, Sehouli J, Richter R, Dimitrova D, et al
    Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer.
    Anticancer Res. 2018;38:4865-4870.
    PubMed     Abstract available


  151. THIEME SF, Collettini F, Sehouli J, Biocca L, et al
    Preoperative Evaluation of Myometrial Invasion in Endometrial Carcinoma: Prospective Intra-individual Comparison of Magnetic Resonance Volumetry, Diffusion-weighted and Dynamic Contrast-enhanced Magnetic Resonance Imaging.
    Anticancer Res. 2018;38:4813-4817.
    PubMed     Abstract available


  152. PRODROMIDOU A, Machairas N, Spartalis E, Kostakis ID, et al
    Transperitoneal Versus Extraperitoneal Laparoscopic Lymphadenectomy for Gynecological Malignancies: A Systematic Review and Meta-analysis.
    Anticancer Res. 2018;38:4677-4681.
    PubMed     Abstract available


  153. TOGASHI K, Okada M, Yamamoto M, Suzuki S, et al
    A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel.
    Anticancer Res. 2018;38:4535-4542.
    PubMed     Abstract available


    July 2018
  154. IZUCHI D, Fukagawa S, Yotsumoto F, Shigekawa K, et al
    Association of Serum HB-EGF Value and Response to Chemotherapy in Patients with Recurrent Ovarian Cancer.
    Anticancer Res. 2018;38:4347-4351.
    PubMed     Abstract available


  155. TAKAHASHI Y, Hamasaki M, Aoki M, Koga K, et al
    Activated EphA2 Processing by MT1-MMP Is Involved in Malignant Transformation of Ovarian Tumours In Vivo.
    Anticancer Res. 2018;38:4257-4266.
    PubMed     Abstract available


  156. ASCIUTTO KC, Forslund O, Borgfeldt C
    Prevalence of High-risk HPV in Postmenopausal Women with Benign Cervical Cytology - A Population-based Cohort Study.
    Anticancer Res. 2018;38:4221-4228.
    PubMed     Abstract available


  157. ARIMA R, Marttila M, Hautakoski A, Arffman M, et al
    Antidiabetic Medication, Statins and the Risk and Prognosis of Non-endometrioid Endometrial Cancer in Women with Type 2 Diabetes.
    Anticancer Res. 2018;38:4169-4178.
    PubMed     Abstract available


  158. LIAO CL, Chu YL, Lin HY, Chen CY, et al
    Bisdemethoxycurcumin Suppresses Migration and Invasion of Human Cervical Cancer HeLa Cells via Inhibition of NF-kB, MMP-2 and -9 Pathways.
    Anticancer Res. 2018;38:3989-3997.
    PubMed     Abstract available


    June 2018
  159. JANSSEN S, Hansen HC, Schild SE, Rades D, et al
    An Instrument for Estimating the 6-Month Survival Probability After Whole-brain Irradiation Alone for Cerebral Metastases from Gynecological Cancer.
    Anticancer Res. 2018;38:3753-3756.
    PubMed     Abstract available


  160. GADDUCCI A, Pistolesi S, Guerrieri ME, Cosio S, et al
    Malignant Transformation in Mature Cystic Teratomas of the Ovary: Case Reports and Review of the Literature.
    Anticancer Res. 2018;38:3669-3675.
    PubMed     Abstract available


  161. TZAFETAS M, Mitra A, Kalliala I, Lever S, et al
    Fertility-sparing Surgery for Presumed Early-stage Invasive Cervical Cancer: A Survey of Practice in the United Kingdom.
    Anticancer Res. 2018;38:3641-3646.
    PubMed     Abstract available


  162. GADDUCCI A, Landoni F, Cosio S, Zizioli V, et al
    Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix - An Italian Multicenter Retrospective Study.
    Anticancer Res. 2018;38:3627-3634.
    PubMed     Abstract available


  163. KREIENBRING K, Franz A, Richter R, Dragun D, et al
    The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer.
    Anticancer Res. 2018;38:3619-3625.
    PubMed     Abstract available


  164. CHUNG T, DO SI, Na K, Kim G, et al
    Stromal p16 Overexpression in Gastric-type Mucinous Carcinoma of the Uterine Cervix.
    Anticancer Res. 2018;38:3551-3558.
    PubMed     Abstract available


  165. AHN SY, Li C, Zhang X, Hyun YM, et al
    Mitofusin-2 Expression Is Implicated in Cervical Cancer Pathogenesis.
    Anticancer Res. 2018;38:3419-3426.
    PubMed     Abstract available


  166. PIRLAMARLA AK, Tang J, Amin B, Kabarriti R, et al
    Vulvar Melanoma with Isolated Metastasis to the Extraocular Muscles: Case Report and Brief Literature Review.
    Anticancer Res. 2018;38:3763-3766.
    PubMed     Abstract available


  167. ASANO M, Matsui J, Towle MJ, Wu J, et al
    Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven(R)): Combination with Anticancer Agents of Differing Mechanisms.
    Anticancer Res. 2018;38:3375-3385.
    PubMed     Abstract available


    May 2018
  168. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Utilization of Hysterectomy Following Chemoradiation for IB2/IIA2 Cervical Cancer in the National Cancer Data Base.
    Anticancer Res. 2018;38:3175-3179.
    PubMed     Abstract available


  169. LUMACHI F, Basso SMM, Camozzi V, Spaziante R, et al
    Bone Mineral Density as a Potential Predictive Factor for Luminal-type Breast Cancer in Postmenopausal Women.
    Anticancer Res. 2018;38:3049-3054.
    PubMed     Abstract available


  170. KISS I, Kolostova K, Matkowski R, Jedryka M, et al
    Correlation Between Disease Stage and the Presence of Viable Circulating Tumor Cells in Endometrial Cancer.
    Anticancer Res. 2018;38:2983-2987.
    PubMed     Abstract available


  171. PHELIPPEAU J, Rouzier R, Koskas M
    Adherence to Guidelines During Follow-up of Endometrial Cancer: Analysis of French Health Insurance Database.
    Anticancer Res. 2018;38:2977-2982.
    PubMed     Abstract available


  172. SLETTEN ET, Arnes M, Vereide AB, Orbo A, et al
    Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.
    Anticancer Res. 2018;38:2883-2889.
    PubMed     Abstract available


  173. SUNG JY, Jung YY, Kim HS
    Clinicopathological Characteristics and KRAS Mutation Status of Endometrial Mucinous Metaplasia and Carcinoma.
    Anticancer Res. 2018;38:2779-2786.
    PubMed     Abstract available


  174. LIN CC, Kuo CL, Huang YP, Chen CY, et al
    Demethoxycurcumin Suppresses Migration and Invasion of Human Cervical Cancer HeLa Cells via Inhibition of NF-kappaB Pathways.
    Anticancer Res. 2018;38:2761-2769.
    PubMed     Abstract available


  175. ARGYRI E, Tsimplaki E, Papatheodorou D, Daskalopoulou D, et al
    Recent Trends in HPV Infection and Type Distribution in Greece.
    Anticancer Res. 2018;38:3079-3084.
    PubMed     Abstract available


  176. KRAMER B, Kneissle M, Birk R, Rotter N, et al
    Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src.
    Anticancer Res. 2018;38:2723-2731.
    PubMed     Abstract available


    April 2018
  177. SCHUSTER S, Joura E, Kohlberger P
    Natural History of Squamous Intraepithelial Lesions in Pregnancy and Mode of Delivery.
    Anticancer Res. 2018;38:2439-2442.
    PubMed     Abstract available


  178. PERRIN M, Bentivegna E, Bonneau C, Uzan C, et al
    Bevacizumab Does Not Reduce the Lymphocele Rate in Advanced Ovarian Cancer After Complete Cytoreductive Surgery.
    Anticancer Res. 2018;38:2247-2252.
    PubMed     Abstract available


  179. TRYBUS W, Krol T, Trybus E, Stachurska A, et al
    Induction of Mitotic Catastrophe in Human Cervical Cancer Cells After Administration of Aloe-emodin.
    Anticancer Res. 2018;38:2037-2044.
    PubMed     Abstract available


    March 2018
  180. GADDUCCI A, Guerrieri ME, Cosio S, Fabrini MG, et al
    Rates, Sites and Times of Recurrence and Clinical Outcome of Endometrial Cancer Patients with Histologically-positive Nodes: An Italian Two-center Retrospective Study.
    Anticancer Res. 2018;38:1695-1703.
    PubMed     Abstract available


  181. FILIPESCU A, Balescu I, Bacalbasa N
    Upper Abdominal Resection for Isolated Metastatic Lesions in Recurrent Cervical Cancer.
    Anticancer Res. 2018;38:1659-1663.
    PubMed     Abstract available


  182. STOPE MB, Cernat V, Kaul A, Diesing K, et al
    Functionality of the Tumor Suppressor microRNA-1 in Malignant Tissue and Cell Line Cells of Uterine Leiomyosarcoma.
    Anticancer Res. 2018;38:1547-1550.
    PubMed     Abstract available


  183. KOENSGEN D, Weiss M, Assmann K, Brucker SY, et al
    Characterization and Management of Borderline Ovarian Tumors - Results of a Retrospective, Single-center Study of Patients Treated at the Department of Gynecology and Obstetrics of the University Medicine Greifswald.
    Anticancer Res. 2018;38:1539-1545.
    PubMed     Abstract available


  184. CANLORBE G, Touboul C, Chargari C, Bentivegna E, et al
    Transitory Stoma at the Time of Complete Cytoreductive Surgery Affects Survival for Patients with Advanced-stage Ovarian Cancer.
    Anticancer Res. 2018;38:1517-1523.
    PubMed     Abstract available


  185. FAHLEN M, Zhang H, Lofgren L, Masironi B, et al
    Expression of Progesterone and Androgen Receptors in the Breast of Premenopausal Women, Considering Menstrual Phase.
    Anticancer Res. 2018;38:1499-1510.
    PubMed     Abstract available


  186. CHUNG EH, Brady PC, Smith KK, Davis MR, et al
    Combined Oocyte Retrieval and Robot-assisted Hysterectomy in a Super Morbidly Obese Patient with Endometrial Carcinoma.
    Anticancer Res. 2018;38:1467-1470.
    PubMed     Abstract available


  187. FISZER-MALISZEWSKA L, Laczmanski L, Dolinska A, Jagas M, et al
    Polymorphisms of ABCB1, CYP3A4 and CYP3A5 Genes in Ovarian Cancer and Treatment Response in Poles.
    Anticancer Res. 2018;38:1455-1459.
    PubMed     Abstract available


  188. NA K, Sung JY, Kim HS
    Clinicopathological Characteristics of High-grade Squamous Intraepithelial Lesions Involving Condyloma Acuminatum.
    Anticancer Res. 2018;38:1767-1774.
    PubMed     Abstract available


    February 2018
  189. HATA M, Koike I, Miyagi E, Asai-Sato M, et al
    Radiation Therapy for Patients with Bone Metastasis from Uterine Cervical Cancer: Its Role and Optimal Radiation Regimen for Palliative Care.
    Anticancer Res. 2018;38:1033-1040.
    PubMed     Abstract available


  190. KALAMPOKAS E, Young H, Bednarek A, Habib M, et al
    Surgical Outcomes and Morbidity After Radical Surgery for Ovarian Cancer in Aberdeen Royal Infirmary, the Northeast of Scotland Gynaecologic Oncology Centre.
    Anticancer Res. 2018;38:923-928.
    PubMed     Abstract available


  191. MATUURA H, Miyamoto M, Takano M, Soyama H, et al
    Low Expression of CD44 Is an Independent Factor of Poor Prognosis in Ovarian Mucinous Carcinoma.
    Anticancer Res. 2018;38:717-722.
    PubMed     Abstract available


  192. ZHAO Y, Xiong GW, Zhang XW, Hang BO, et al
    Is Ki-67 of Diagnostic Value in Distinguishing Between Partial and Complete Hydatidiform Moles? A Systematic Review and Meta-analysis.
    Anticancer Res. 2018;38:1105-1110.
    PubMed     Abstract available


    January 2018
  193. BRUCKNER HW, Gurell D, Hirschfeld A
    Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
    Anticancer Res. 2018;38:547-552.
    PubMed     Abstract available


  194. OKONOGI N, Wakatsuki M, Kato S, Shiba S, et al
    Long-term Outcomes of Carbon-ion Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Uterine Cervix.
    Anticancer Res. 2018;38:457-463.
    PubMed     Abstract available


  195. BACALBASA N, Balescu I, Brasoveanu V, Anca AF, et al
    Debulking Surgery for Pelvic Recurrence After Surgically-treated Tubal Gestational Choriocarcinoma - A Case Report and Literature Review.
    Anticancer Res. 2018;38:423-426.
    PubMed     Abstract available


  196. MIYAMOTO M, Takano M, Aoyama T, Soyama H, et al
    Phenoxodiol Increases Cisplatin Sensitivity in Ovarian Clear Cancer Cells Through XIAP Down-regulation and Autophagy Inhibition.
    Anticancer Res. 2018;38:301-306.
    PubMed     Abstract available


  197. KOBIERZYCKI C, Piotrowska A, Latkowski K, Zabel M, et al
    Correlation of Pyruvate Kinase M2 Expression with Clinicopathological Data in Ovarian Cancer.
    Anticancer Res. 2018;38:295-300.
    PubMed     Abstract available


  198. SOUKUP V, Capoun O, Pesl M, Sobotka R, et al
    Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A.
    Anticancer Res. 2018;38:239-246.
    PubMed     Abstract available


  199. PELISSIER A, Franke O, Darai E, Houvenaeghel G, et al
    Value of Diaphragmatic Surgery During Interval Debulking Surgery.
    Anticancer Res. 2018;38:411-416.
    PubMed     Abstract available


    December 2017
  200. LEE HJ, Lee YH, Chong GO, Hong DG, et al
    Robotic-assisted Transperitoneal Infrarenal Para-aortic Lymphadenectomy for Gynecological Malignancies: Comparison with a Laparoscopic Approach.
    Anticancer Res. 2017;37:7087-7093.
    PubMed     Abstract available


  201. NIIBE Y, Onda T, Matsuo K, Inoue Y, et al
    Phase II Study of Concurrent Chemoradiotheapy Using Nedaplatin for Locally Advanced Uterine Cervical Carcinoma (KGROG0501): Final Results.
    Anticancer Res. 2017;37:6983-6988.
    PubMed     Abstract available


  202. MOURAD WF, Packianathan S, Yan W, Pishgou M, et al
    Reliable Radiation Technique to Minimize Ovarian Dose During Radiation Prophylaxis of Heterotopic Ossification.
    Anticancer Res. 2017;37:6929-6935.
    PubMed     Abstract available


  203. TINELLI G, Cappuccio S, Parente E, Fagotti A, et al
    Resectability and Vascular Management of Retroperitoneal Gynecological Malignancies: A Large Single-institution Case-Series.
    Anticancer Res. 2017;37:6899-6906.
    PubMed     Abstract available


  204. DUCOULOMBIER S, Golfier F, Colomban O, Benayoun D, et al
    Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer.
    Anticancer Res. 2017;37:6879-6886.
    PubMed     Abstract available


  205. KOENSGEN D, Besic I, Gumbel D, Kaul A, et al
    Cold Atmospheric Plasma (CAP) and CAP-Stimulated Cell Culture Media Suppress Ovarian Cancer Cell Growth - A Putative Treatment Option in Ovarian Cancer Therapy.
    Anticancer Res. 2017;37:6739-6744.
    PubMed     Abstract available


  206. NA K, Sung JY, Kim HS
    TP53 Mutation Status of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma with a Wild-type p53 Immunostaining Pattern.
    Anticancer Res. 2017;37:6697-6703.
    PubMed     Abstract available


  207. KUITTINEN T, Rovio P, Staff S, Luukkaala T, et al
    Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells In Vitro.
    Anticancer Res. 2017;37:6575-6581.
    PubMed     Abstract available


  208. RAPI V, Dogan A, Schultheis B, Hartmann F, et al
    Melanoma of the Vagina: Case Report and Systematic Review of the Literature.
    Anticancer Res. 2017;37:6911-6920.
    PubMed     Abstract available


  209. BAVELLONI A, Ramazzotti G, Poli A, Piazzi M, et al
    MiRNA-210: A Current Overview.
    Anticancer Res. 2017;37:6511-6521.
    PubMed     Abstract available


    November 2017
  210. KIM SM, Rhee YH, Kim JS
    The Anticancer Effects of Radachlorin-mediated Photodynamic Therapy in the Human Endometrial Adenocarcinoma Cell Line HEC-1-A.
    Anticancer Res. 2017;37:6251-6258.
    PubMed     Abstract available


  211. YANG Y, Li X, Mamouni K, Kucuk O, et al
    Mifepristone Has Limited Activity to Enhance the In Vivo Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate Cancer.
    Anticancer Res. 2017;37:6235-6243.
    PubMed     Abstract available


  212. NAKATANI M, Watari H, Mitamura T, Wang L, et al
    The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma In Vitro and In Vivo.
    Anticancer Res. 2017;37:6125-6132.
    PubMed     Abstract available


  213. TRYBUS W, Krol T, Trybus E, Kopacz-Bednarska A, et al
    Changes in the Lysosomal System of Cervical Cancer Cells Induced by Emodin Action.
    Anticancer Res. 2017;37:6087-6096.
    PubMed     Abstract available


  214. GADDUCCI A, Guerrieri ME
    Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
    Anticancer Res. 2017;37:5955-5965.
    PubMed     Abstract available


    October 2017

  215. Translational Advances in Gynecologic Cancers. 1st Edition.
    Anticancer Res. 2017;37:5907.
    PubMed    


  216. BACALBASA N, Balescu I, Filipescu A
    Debulking Surgery for Clear Cell Carcinoma of the Ovary - A Case Report and Literature Review.
    Anticancer Res. 2017;37:5707-5711.
    PubMed     Abstract available


  217. SHIBA S, Okonogi N, Kato S, Wakatsuki M, et al
    Clinical Impact of Re-irradiation with Carbon-ion Radiotherapy for Lymph Node Recurrence of Gynecological Cancers.
    Anticancer Res. 2017;37:5577-5583.
    PubMed     Abstract available


  218. PARK CK, Kim HS
    Clinicopathological Characteristics of Ovarian Sclerosing Stromal Tumor with an Emphasis on TFE3 Overexpression.
    Anticancer Res. 2017;37:5441-5447.
    PubMed     Abstract available


  219. GLASSMAN D, Hignett S, Rehman S, Linforth R, et al
    Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update.
    Anticancer Res. 2017;37:5329-5341.
    PubMed     Abstract available


  220. KAWAHARA H, Akiba T, Yanaga K
    Transanal Assisted Resection with Closure of Anal Canal for Lower Rectal Diseases.
    Anticancer Res. 2017;37:5767-5769.
    PubMed     Abstract available


  221. GUNGORDUK K, Asicioglu O, Braicu EI, Almuheimid J, et al
    The Impact of Surgical Staging on the Prognosis of Mucinous Borderline Tumors of the Ovaries: A Multicenter Study.
    Anticancer Res. 2017;37:5609-5616.
    PubMed     Abstract available


    September 2017
  222. ANNEDE P, Darreon J, Benkemouche A, Valdenaire S, et al
    Flattening Filter Free vs. Flattened Beams for Lung Stereotactic Body Radiation Therapy.
    Anticancer Res. 2017;37:5133-5139.
    PubMed     Abstract available


  223. VORA M, Alattia LA, Ansari J, Ong M, et al
    Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia.
    Anticancer Res. 2017;37:4821-4825.
    PubMed     Abstract available


  224. SUKOVAS A, Cesna V, Jasukaitiene A, Barauskas G, et al
    Response of OVCAR-3 Cells to Cisplatin and Hyperthermia: Does Hyperthermia Really Matter?
    Anticancer Res. 2017;37:5011-5018.
    PubMed     Abstract available


  225. KASE S, Ishijima K, Uraki T, Suimon Y, et al
    Usefulness of Flow Cytometry in Diagnosis of IgG4-Related Ophthalmic Disease and Extranodal Marginal Zone B-Cell Lymphoma of the Ocular Adnexa.
    Anticancer Res. 2017;37:5001-5004.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: